Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: An autoradiographic study with [3H]citalopram

doi:10.1016/0306-4522(93)90240-G

Neuroscience

Volume 54, Issue 3, June 1993, Pages 691-699

https://doi.org/10.1016/0306-4522(93)90240-G Get rights and content

Abstract

Receptor autoradiography with [³H]citalopram as ligand was used to study the distribution of serotonin uptake binding sites in post mortem brain tissues from patients with Parkinson's disease, progressive supranuclear palsy and from age-matched controls. Significant decreases in [³H]citalopram binding sites were found in the cerebral cortex of patients with Parkinson's disease and progressive supranuclear palsy. Densities of [³H]citalopram binding sites were significantly reduced in all components of the basal ganglia of Parkinson's disease but only in the head of caudate nucleus of progressive supranuclear palsy patients. The density of [³H]citalopram binding sites in the raphe nuclei of Parkinson's disease was comparable to control values.

Our results suggest that serotoninergic terminals are differentially affected in Parkinson's disease and in progressive supranuclear palsy.

Reference (60)

AgidY. et al.
Peptides and Parkinson's disease
Trends Neurosci.
(1985)
CashR. et al.
High and low affinity [³H]imipramine binding sites in control and Parkisonian brains
Eur. J. Pharmac.
(1985)
ChinagliaG. et al.
Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [³H]mazindol
Neuroscience
(1992)
CortésR. et al.
Autoradiography of antidepressant binding sites in the human brain: localization using [³H]imipramine and [³H]paroxetine
Neuroscience
(1988)
FolsteinM.F. et al.
“Mini-mental state”, a practical method for grading the cognitive state of patients for the clinician
J. psychiat. Res.
(1975)
HallidayG.M. et al.
Loss of brainstem serotoninand substance P-containing neurons in Parkinson's disease
Brain Res.
(1990)
HyttelJ.
Citalopram. Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity
Prog. Neuropsychopharmac. biol. Psychiat.
(1982)
IshinoH. et al.
Contribution to clinical pathology of progressive supranuclear palsy (subcortocal argyrophilic dystrophy) On the distribution of neurofibrillary tangles in the basal ganglia and brain-stem and its clinical significance
J. neurol. Sci.
(1975)
MamounasL.A. et al.
Evidence for dual serotonergic projections to neocortex: axons from the dorsal and median raphe nuclei are differentially vulnerable to the neurotoxin p-Chloroamphetamine (PCA)
Expl Neurol.
(1988)
OberlanderC. et al.
Distinct functions for dopamine and serotonin in locomotor behaviour: evidence using the 5-HT, agonist RU 24969 in globus pallidus-lesioned rats
Neurosci. Lett.
(1986)

OlpeH.R. et al.

The response of striatal cells upon stimulation of the dorsal and median raphe nuclei

Brain Res.

(1977)

PiflCh. et al.

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey

Neuroscience

(1991)

ScattonB. et al.

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease

Brain Res.

(1983)

SoubriéP. et al.

Functional aspects of serotonin transmission in the basal ganglia: a review and an in vivo approach using push-pull cannula technique

Neuroscience

(1984)

TörkI. et al.

Raphe nuclei and the serotonergic system

WaeberC. et al.

Serotonin 1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiographic study

Neuroscience

(1989)

AgidY. et al.

Progressive supranuclear palsy: anatomoclinical and biochemical considerations

AzmitiaE.C. et al.

An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat

J. comp. Neurol.

(1978)

BattagliaG. et al.

3,4-Methylendioxymethamphetamine (MDMA) and 3,4-methylendioxyamphetamine (MDA) preferentially destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of³H-paroxetine-labeled serotonin uptake sites

J. Pharmac. exp. Ther.

(1987)

BernheimerM. et al.

Verteilung des 5-hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom

Klin. Wschr.

(1961)

BirkmayerW. et al.

Serotonin and extrapyramidal disorders

BlakelyR.D. et al.

Cloning and expression of a functional serotonin transporter from rat brain

Nature

(1991)

BlierP. et al.

Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression

J. clin. Psychopharmac.

(1987)

BrooksD.J. et al.

Differing patterns of striatal¹⁸F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Ann. Neurol.

(1990)

CrossA.J.

Serotonin in neurodegenerative disorders

D'AmatoR.J. et al.

Selective labeling of serotonin uptake sites in rat brain by [³H]citalopram contrasted to labeling of multiple sites by [³H]imipramine

J. Pharmac. exp. Ther.

(1987)

D'AmatoR.J. et al.

Aminergic systems in Alzheimer's disease and Parkinson's disease

Ann. Neurol.

(1987)

DeArmondS.J. et al.

Structure of the Human Brain: a Photographic Atlas

DrayA.

Serotonin in the basal ganglia: functions and interactions with other neuronal pathways

J. Physiol.

(1981)

GibbW.R.G.

Neuropathology in movement disorders

J. Neurol. Neurosurg. Psvchiat.

(1989)

Cited by (118)

Symptomatic relief of constant groaning in progressive supranuclear palsy with escitalopram
2022, Parkinsonism and Related Disorders
Serotonergic imaging in Parkinson's disease
2021, Progress in Brain Research
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive degeneration of monoaminergic central pathways such as the serotonergic. The degeneration of serotonergic signaling in striatal and extrastriatal brain regions is an early feature of PD and is associated with several motor and non-motor complications of the disease. Molecular imaging techniques with Positron Emission Tomography (PET) have greatly contributed to the investigation of biological changes in vivo and to the understanding of the extent of serotonergic pathology in patients or individuals at risk for PD. Such discoveries provide with opportunities for the identification of new targets that can be used for the development of novel disease-modifying drugs or symptomatic treatments. Future studies of imaging serotonergic molecular targets will better clarify the importance of serotonergic pathology in PD, including progression of pathology, target-identification for pharmacotherapy, and relevance to endogenous synaptic serotonin levels. In this article, we review the current status and understanding of serotonergic imaging in PD.
Synthesis and evaluation of 2-(2′-((dimethylamino)methyl)-4′-(2-fluoroethoxy-substituted)phenylthio)benzenamine derivatives as potential positron emission tomography imaging agents for serotonin transporters
2020, Bioorganic Chemistry
Citation Excerpt :
Serotonin (5-HT) is involved in a wide variety of physiological functions through its interaction with 14 serotonin receptor subtypes. Dysregulation of serotonin transmission is known to be involved in various neuropsychiatric and neurodegenerative diseases/disorders, such as depression, anxiety, obsessive-compulsive disorder, eating disorder, addiction, Parkinson’s disease, and Alzheimer’s disease [1–8]. In the central nervous system (CNS), serotonin transporters (SERT) are responsible for the reuptake of extracellular 5-HT from the synapse into the presynaptic nerves to terminate its downstream action, and high densities of SERT have been observed in the raphe nuclei, caudate, putamen, thalamus, hypothalamus, and amygdala, with lower densities in the cortex and cerebellum [9].
A series of diphenylsulfide derivatives with various substitutions at the 4-position on phenyl ring A and different lengths of the 2-fluoroethoxy-substituted side-chain at the 4′-position on ring B were synthesized and evaluated as potential positron emission tomography (PET) imaging agents for serotonin transporters (SERT). These ligands exhibited high SERT binding affinities (K_i = 0.11–1.3 nM) and the 4-methyl-substituted (4-Me) compounds 7a and 8a displayed excellent selectivity for SERT versus norepinephrine transporters (NET) (392- and 700-fold, respectively). In the parallel artificial membrane permeability assay (PAMPA), these ligands demonstrated moderate to high brain penetration, and the 4-Me analogs showed higher BBB permeability than the corresponding 4-F analogs. The 2-fluoroethoxy-substituted ligands showed higher metabolic stability and lower lipophilicity than 4-F-ADAM. [¹⁸F]7a-c were readily prepared using an automatic synthesizer and exhibited significant uptake and slow washout in rat brains. At 120 min after iv injection, [¹⁸F]7a exhibited the highest uptake in the midbrain, whereas [¹⁸F]7b exhibited the highest uptake in the hypothalamus and midbrain. After treatment with citalopram, a SERT-selective ligand, the uptake of [¹⁸F]7a in the hypothalamus and striatum was significantly decreased. The potent and highly selective SERT binding and the selective and reversible accumulation in SERT-rich brain regions suggested that [¹⁸F]7a is a promising lead for the further development of novel [¹⁸F]-labeled PET imaging agents for SERT binding sites in the brain.
Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration
2019, Handbook of Clinical Neurology
Citation Excerpt :
5-HT in postmortem brains of PSP patients was investigated further in subsequent studies, though the results are conflicting. For example, in an immunohistochemistry study, Kovacs et al. (2003) detected a significant increase in serotoninergic neurons in the raphe nuclei, whereas when Chinaglia et al. (1993) used autoradiography, they observed a decrease in serotoninergic transporters in the cortex and caudate nucleus, though this finding was not confirmed later by Landwehrmeyer and Palacios (1994). An increase in postsynaptic 5-HT-receptors, particularly in the substantia nigra, was reported by Castro et al. (1998), who used [3H] sumatriptan, a 5-HT1B/1D-receptor ligand.
Progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD) are forms of parkinsonism. PSP and CBD are 4R tauopathies and clinicopathologic overlaps exist between these two disorders. Neuropsychiatric symptoms including apathy, depression, anxiety are common features in patients with PSP and CBD. Disinhibition and impulsive behavior are also frequently observed in PSP patients, whereas hallucinations are seen only occasionally. Severe derangement in several neurotransmitter systems may account for behavioral symptoms observed in PSP and CBD, but substitutive therapy is not effective. Recent advances in genetics, epidemiology, biomarkers, pathophysiology, molecular mechanisms, and, in particular, the availability of treatments that may modify disease progression are opening new hopes in the care of these devastating disorders. MSA is a synucleinopathy with well characterized motor and autonomic dysfunction. MSA patients frequently show the presence of rapid eye movement (REM) behavior disorders, but the impact of neuropsychiatric disturbances and cognitive impairment in MSA needs further study. The availability of animal models and recent advances in the pathophysiology of α-synuclein accumulation are shedding light on the disease, opening new avenues for possible treatments.
Fully automated one-pot two-step synthesis of 4-[<sup>18</sup>F]-ADAM, a potent serotonin transporter imaging agent
2016, Applied Radiation and Isotopes
Citation Excerpt :
Dysfunction of serotonin transporter (SERT) has been implicated in several neuro-psychiatric disorders (Chinaglia et al., 1993; Mann et al., 2000; Meltzer et al., 1998).
N,N-dimethyl-2-(2-amino-4-[¹⁸F]fluorophenylthio)benzylamine (4-[¹⁸F]-ADAM, 2) is a potent serotonin transporter (SERT) imaging agent. In order to fulfill the demand of clinical studies, we have developed a fully automated one-pot two-step synthesis of this potent SERT imaging agent.
The 4-[¹⁸F]-ADAM (2) was synthesized using a commercially available GE TRACERlab FN module. Briefly, the precursor, N,N-dimethyl-2-(2,4-dinitrophenylthio) benzylamine (1) in DMSO was reacted with K[¹⁸F]/K_2.2.2 in a glassy carbon reaction vessel at 120 °C for 7.5 min followed by reduction of the intermediate with NaBH₄/Cu(OAc)₂ in EtOH in the same vessel at 80 °C for 20 min. The reaction mixture was then purified with high-performance liquid chromatography (HPLC) and solid phase extraction (SPE) to give (2). The quality of (2) synthesized by this method was verified by HPLC and TLC as compared to its authentic sample synthesized by two-pot two-step method.
Using this automated one-pot two-step method, the radiochemical yield (RCY) of (2) was 2.5±0.8% (n=12, EOS) in a synthesis time of 100±6 min from EOB with a specific activity of 4.4±1.9 Ci/μmol (n=12, EOS). Radioligand (2) was stable over 4 h at room temperature.
This fully automated one-pot two-step synthetic method using a commercially available GE TRACERlab FN module could simplify the synthesis of 4-[¹⁸F]-ADAM (2) and fulfill its demand for both animal and human studies, especially for study sites without a cyclotron.
Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment
2016, Neuroscience
Our recent study has indicated that a moderate lesion induced by bilateral 6-hydroxydopamine (6-OHDA) injections into the ventrolateral region of the caudate-putamen (CP) in rats, modeling preclinical stages of Parkinson’s disease, induces a “depressive-like” behavior which is reversed by chronic treatment with pramipexole (PRA).
The aim of the present study was to examine the influence of the above lesion and chronic PRA treatment on binding to the serotonin transporter (SERT) in different brain regions. As before, 6-OHDA (15 μg/2.5 μl) was administered bilaterally into the CP. PRA (1 mg/kg) was injected subcutaneously twice a day for 2 weeks. Serotonergic and dopaminergic neurons of the dorsal raphe (DR) were immunostained for tryptophan hydroxylase and tyrosine hydroxylase, respectively, and were counted stereologically. Binding of [³H]GBR 12,935 to the dopamine transporter (DAT) and [³H]citalopram to SERT was analyzed autoradiographically. Intrastriatal 6-OHDA injections decreased the number of dopaminergic, but not serotonergic neurons in the DR. 6-OHDA reduced the DAT binding in the CP, and SERT binding in the nigrostriatal system (CP, substantia nigra (SN)), limbic system (ventral tegmental area (VTA), nucleus accumbens (NAC), amygdala, prefrontal cortex (PFCX), habenula, hippocampus) and DR. A significant positive correlation was found between DAT and SERT binding in the CP. Chronic PRA did not influence DAT binding but reduced SERT binding in the above structures, and deepened the lesion-induced losses in the core region of the NAC, SN, VTA and PFCX.
The present study indicates that both the lesion of dopaminergic neurons and chronic PRA administration induce adaptive down-regulation of SERT binding. Moreover, although involvement of stimulation of dopaminergic transmission by chronic PRA in its “antidepressant” effect seems to be prevalent, additional contribution of SERT inhibition cannot be excluded.

View all citing articles on Scopus

^†: Present address: Clinica Neurologica I

View full text

Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: An autoradiographic study with [3H]citalopram

Abstract

Trends Neurosci.

Eur. J. Pharmac.

Neuroscience

Neuroscience

J. psychiat. Res.

Brain Res.

Prog. Neuropsychopharmac. biol. Psychiat.

J. neurol. Sci.

Expl Neurol.

Neurosci. Lett.

Brain Res.

Neuroscience

Brain Res.

Neuroscience

Neuroscience

Progressive supranuclear palsy: anatomoclinical and biochemical considerations

An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat

J. comp. Neurol.

3,4-Methylendioxymethamphetamine (MDMA) and 3,4-methylendioxyamphetamine (MDA) preferentially destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of3H-paroxetine-labeled serotonin uptake sites

J. Pharmac. exp. Ther.

Verteilung des 5-hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom

Klin. Wschr.

Serotonin and extrapyramidal disorders

Cloning and expression of a functional serotonin transporter from rat brain

Nature

Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression

J. clin. Psychopharmac.

Differing patterns of striatal18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Ann. Neurol.

Serotonin in neurodegenerative disorders

Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine

J. Pharmac. exp. Ther.

Aminergic systems in Alzheimer's disease and Parkinson's disease

Ann. Neurol.

Structure of the Human Brain: a Photographic Atlas

Serotonin in the basal ganglia: functions and interactions with other neuronal pathways

J. Physiol.

Neuropathology in movement disorders

J. Neurol. Neurosurg. Psvchiat.

Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: An autoradiographic study with [³H]citalopram

3,4-Methylendioxymethamphetamine (MDMA) and 3,4-methylendioxyamphetamine (MDA) preferentially destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of³H-paroxetine-labeled serotonin uptake sites

Differing patterns of striatal¹⁸F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Selective labeling of serotonin uptake sites in rat brain by [³H]citalopram contrasted to labeling of multiple sites by [³H]imipramine